The Investing News rounds some of the biggest news in the cannabis market for the past trading week
By Shelly Kumar
RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders, including sleep apnea, opioid-induced respiratory depression, and respiratory insufficiency due to spinal cord injury, announces that the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, James
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
The Investing News reported took a closer look at some of the big cannabis news of the week and published an interview with the president of Cannabis Wheaton.
CURE Pharmaceutical announced its subsidiary Oak Therapeutics completed a milestone as part of their research contract with the National Institutes of Health and National Institute of Allergy and Infectious Diseases to develop 300mg of Isoniazid in a rapidly dissolving Oral Dissolvable Strip as an antituberculosis treatment.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
This past trading in the cannabis marketplace saw another major dip to the Marijuana Life Sciences Index, the first medical marijuana study funded by a US medical government research group.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
Opiant Pharmaceuticals shared a set of results from its Phase 1 trial of OPNT002.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.
GeoVax Labs released their financial results for the first quarter of 2017 and gave updates on the state of its various vaccines.
Inovio Pharmaceuticals announced its Ebola vaccine showed promising preliminary results from an expanded Phase I study.
GeoVax Labs has successfully concluded a clinical trial for its vaccine candidate GEO-ZM02 seeking protection for the Zika virus.